secwatch.observer — SEC 8-K summary
======================================

Issuer:     QUEST DIAGNOSTICS INC (DGX)
CIK:        0001022079
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001022079-23-000091
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quest Diagnostics Q1 revenue falls 10.7% to $2.33B; acquires Haystack Oncology for $300M
--------------------------------------------------------------------------------

- Q1 net revenue $2.33B, down 10.7% YoY; base business revenue up 10% to $2.21B.
- Reported diluted EPS $1.78 (down 39%); adjusted diluted EPS $2.04 (down 36.6%).
- Full-year 2023 guidance: revenue $8.93B-$9.08B, adjusted EPS $8.45-$8.95.
- Acquires Haystack Oncology for $300M cash at close plus up to $150M milestones; MRD liquid biopsy tech.
- Deal expected to close Q2 2023; modest dilution for 3 years, accretive by 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022079/000102207923000091/0001022079-23-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022079/000102207923000091/dgx-20230427.htm
  HTML page:      https://secwatch.observer/filing/0001022079-23-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer